Use of Vigabatrin in Super Refractory Status Epilepticus – An Update
This poster is part of a Virtual Poster Session, hosted by the Ochsner Continuing Medical Education. We encourage you to ask questions and engage in discussion on this poster! Authors will respond to comments between May 25- June 5, 2020.
Presenters
Mugilan Poongkunran, MD¹; Vivek Sabharwal, MD¹; Fawad Khan, MD¹; Neil Billeaud, MD¹; Carolina Maciel, MD²; Laura Ades, MD¹; Uma Menon, MD¹; R. Eugene Ramsay, MD¹
¹Ochsner Medical Center, New Orleans, LA; ²University of Florida, Gainesville, FL
Poster
(Click here to access this presentation as a PDF.)
Very interesting update. How many AEDs were trialed on average prior to starting VGB?
Thanks for your response. On a average 4 AEDs prior to VGB – that includes high-dosing of propofol infusions
Helpful to know that we can use vigabatrin in challenging case of SRSE.
Where there other anesthetics aside from Propofol and ketamine were used as 44 had either medication but 70 were on anesthetics? Was ease of control with VGB related to underlying neurological injury – shorter vs, longer latency to control?
Very interesting use of VGB. I too, would like to know how many AEDs were trialed on average prior to starting VGB?
Would this be applicable to the pediatric population as well?
And is there a concern that the VBG therapy may have attributed to the mortality of the 25 patients? Or is it considered completely un-related?
Is the reported mortality from multiorgan failure (36%) a drug effect or disease effect?
Thanks for your response. On a average 4 AEDs prior to VGB – that includes high-dosing of propofol infusions.
Our analysis had only 2 pediatric patients included – one was infant and both SRSE resolution. Otherwise, the analysis is mainly pertinent to adult population. However, expert opinions have suggested its use in pediatric population.
Mortality and VGB – no temporal association from our analysis. Retrospective limitations exist.
Excellent!